Carrier screening for gaucher disease: Lessons for low-penetrance, treatable diseases

JAMA

Volumn 298, Issue 11, 2007, Pages 1281-1290

  Zuckerman, Shachar ^b,c   Lahad, Amnon ^a,b   Shmueli, Amir ^b   Zimran, Ari ^b,c   Peleg, Leah ^d   Orr Urtreger, Avi ^e   Levy Lahad, Ephrat ^b,c   Sagi, Michal ^b,f  

^a Department of Family Medicine ^*  (Israel)

^b HEBREW UNIVERSITY   (Israel)

^c SHAARE ZEDEK MEDICAL CENTER   (Israel)

^d GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^e TEL AVIV UNIVERSITY   (Israel)

^f HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; GAUCHER DISEASE; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC RISK; HETEROZYGOTE; HETEROZYGOTE DETECTION; HUMAN; ISRAEL; JEW; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; OUTCOME ASSESSMENT; PREDICTION; PREGNANCY; PREGNANCY TERMINATION; PRENATAL DIAGNOSIS; PRETEST POSTTEST CONTROL GROUP DESIGN; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; TELEPHONE; GENETIC SCREENING; GENETICS; INDUCED ABORTION; MIDDLE AGED; STATISTICS; UTILIZATION REVIEW;

ABORTION, INDUCED; ADULT; FEMALE; GAUCHER DISEASE; GENETIC COUNSELING; GENETIC SCREENING; HETEROZYGOTE; HUMANS; ISRAEL; JEWS; MALE; MIDDLE AGED; PREGNANCY; PRENATAL DIAGNOSIS; RISK ASSESSMENT;

EID: 34548770576     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.298.11.1281     Document Type: Article

References (50)

1. Cao A, Rosatelli MC, Galanello R. Population-based genetic screening. Curr Opin Genet Dev. 1991;1(1):48-53.
2. Vallance H, Ford J. Carrier testing for autosomal-recessive disorders. Crit Rev Clin Lab Sci. 2003;40(4):473-497.
3. Burke W, Coughlin SS, Lee NC, Weed DL, Khoury MJ. Application of population screening principles to genetic screening for adult-onset conditions. Genet Test. 2001;5(3):201-211.
4. Kaback MM. Population-based genetic screening for reproductive counseling: the Tay-Sachs disease model. Eur J Pediatr. 2000;159(suppl 3):S192-S195.
5. Kronn D, Jansen V, Ostrer H. Carrier screening for cystic fibrosis, Gaucher disease, and Tay-Sachs disease in the Ashkenazi Jewish population: the first 1000 cases at New York University Medical Center, New York, NY. Arch Intern Med. 1998;158(7):777-781.
6. The Victor Outreach and Screening Program for Ashkenazi Jewish. Tufts-New England Medical Center Web site. http://nemc.org/jewishgeneticscreening/ about_us/the_victor_program.aspx. Accessed April 29, 2007.
7. Human Genetics Program. New York University Medical Center. http://www.med.nyu.edu/genetics/lab/ashkenazi_screen.html. Accessed April 29, 2007.
8. Horowitz M, Pasmanik-Chor M, Borochowitz Z, et al. Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population. Hum Mutat. 1998;12(4):240-244.
9. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249-254.
10. Poorthuis BJ, Wevers RA, Kleijer WJ, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999;105(1-2):151-156.
11. Beutler E, Gelbart T, Kuhl W, Zimran A, West C. Mutations in Jewish patients with Gaucher disease. Blood. 1992;79(7):1662-1666.
12. Beutler E, Grabowski GA. Gaucher disease. In: Scriver CR, Sly WS, Childs B, Beaudet AL, Valle D, Kinzler KW, Vogelstein B, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001:3635-3668.
13. Beutler E, Nguyen NJ, Henneberger MW, et al. Gaucher disease: gene frequencies in the Ashkenazi Jewish population. Am J Hum Genet. 1993;52(1):85-88.
14. Azuri J, Elstein D, Lahad A, Abrahamov A, Hadas-Halpern I, Zimran A. Asymptomatic Gaucher disease implications for large-scale screening. Genet Test. 1998;2(4):297-299.
15. Elstein D, Scott CR, Zeigler M, Abrahamov A, Zimran A. Phenotypic heterogeneity in patients with Gaucher disease and the N370S/V394L genotype. Genet Test. 2005;9(1):26-29.
16. Beutler E. Enzyme replacement therapy for Gaucher's disease. Baillieres Clin Haematol. 1997;10(4):751-763.
17. Weinreb NJ, Charrow J, Andersson HC, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med. 2002;113(2):112-119.
18. Kesselman I, Elstein D, Israeli A, Chertkoff R, Zimran A. National health budgets for expensive orphan drugs: Gaucher disease in Israel as a model. Blood Cells Mol Dis. 2006;37(1):46-49.
19. Heitner R, Elstein D, Aerts J, Weely S, Zimran A. Low-dose N417 butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol Dis. 2002;28(2):127-133.
20. Wilson JMG, Jungner G. Principles and Practice of Screening for Disease. Geneva, Switzerland: World Health Organization Chronicle; 1968:473.
21. Williamson R. Universal community carrier screening for cystic fibrosis? Nat Genet. 1993;3(3):195-201.
22. Sagi M. Ethical aspects of genetic screening in Israel. Sci Context. 1998;11(3-4):419-429.
23. Gaucher disease: current issues in diagnosis and treatment: NIH Technology Assessment Panel on Gaucher Disease. JAMA. 1996;275(7):548-553.
24. Langlois S, Wilson RD. Genetics Committee of the Society of Obstetricians and Gynaecologists of Canada (SOGC); Prenatal Diagnosis Committee of the Canadian College of Medical Geneticists (CCMG). Carrier screening for genetic disorders in individuals of Ashkenazi Jewish descent. J Obstet Gynaecol Can. 2006;28(4):324-343.
25. Zimran A, Zaizov R, Zlotogora J. Large scale screening for Gaucher's disease in Israel: a position paper by the National Gaucher Committee of the Ministry of Health. Harefuah. 1997;133(3-4):107-108.
26. Chicago Center for Jewish Genetic Disorders. http://www. jewishgeneticscenter.org/what/. Accessed April 29, 2007.
27. Quest Diagnostics. http://www.questdiagnostics.com. Accessed April 29, 2007.
28. Wallerstein R, Starkman A, Jansen V. Carrier screening for Gaucher disease in couples of mixed ethnicity. Genet Test. 2001;5(1):61-64.
29. Strom CM, Crossley B, Redman JB, et al. Molecular screening for diseases frequent in Ashkenazi Jews: lessons learned from more than 100,000 tests performed in a commercial laboratory. Genet Med. 2004;6(3):145-152.
30. Eng CM, Schechter C, Robinowitz J, et al. Prenatal genetic carrier testing using triple disease screening. JAMA. 1997;278(15):1268-1272.
31. GeneReviews Web site. http://www.geneclinics.org/servlet/access. Accessed April 29, 2007.
32. Brautbar A, Elstein D, Abrahamov A, et al. The 1604A (R496H) mutation in Gaucher disease: genotype/phenotype correlation. Blood Cells Mol Dis. 2003;31(2):187-189.
33. Allitto BA, Finn PB, Napolitano NM, et al. Prevalence of the 1604A Gaucher disease mutation in unaffected Ashkenazi Jewish individuals [abstract]. Am J Hum Genet. 1997;61(4)(suppl):A325.
34. Zimran A, Horowitz M. RecTL: a complex allele of the glucocerebrosidase gene associated with a mild clinical course of Gaucher disease. Am J Med Genet. 1994;50(1):74-78.
35. Zimran A, Kay A, Gelbart T, et al. Gaucher disease: clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore). 1992;71(6):337-353.
36. Connock M, Burls A, Frew E, et al. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review. Health Technol Assess. 2006;10(24):iii-iv, ix-136.
37. Elstein D, Abrahamov A, Hadas-Halpern I, Meyer A, Zimran A. Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease. QJM. 1998;91(7):483-488.
38. Genetic tests before and during pregnancy. Israel Ministry of Health's Community Genetics Web site. http://www.health.gov.il/pages/default.asp?maincat= 42. Accessibility verified August 21, 2007.
39. Israel Ministry of Health's Community Genetics Web site. http://www.health.gov.il/Download/pages/genetic_test_torashti.pdf. Accessibility verified August 21, 2007.
40. Lilani A. Ethical issues and policy analysis for genetic testing: Huntington's disease as a paradigm for diseases with a late onset. Hum Reprod Genet Ethics. 2005;11(2):28-34.
41. Zimran A, Abrahamov A, Elstein D. Children with type I Gaucher disease: growing into adulthood with and without enzyme therapy. Isr Med Assoc J. 2000;2(2):80-81.
42. Ekstein J, Katzenstein H. The Dor Yeshorim story: community-based carrier screening for Tay-Sachs disease. Adv Genet. 2001;44:297-310.
43. Kannai R, Chertok IR. Prenatal panel screening considerations for non-neuronopathic Gaucher disease in the Ashkenazi-Jewish population. Isr Med Assoc J. 2006;8(5):347-350.
44. Wertz DC, Knoppers BM. Serious genetic disorders: can or should they be defined? Am J Med Genet. 2002;108(1):29-35.
45. Position paper: carrier screening for Gaucher disease [pamphlet]. Chapter in position papers: Carrier Screening for Genetic Disease. Ramat Gan, Israel: Israel Medical Association; 2004.
46. Kogan A, Shinar Y, Lidar M, et al. Common MEFV mutations among Jewish ethnic groups in Israel: high frequency of carrier and phenotype III states and absence of a perceptible biological advantage for the carrier state. Am J Med Genet. 2001;102(3):272-276.
47. Ben-Chetrit E, Abeliovich D. The distribution of MEFV common mutations among Israeli patients with familial Mediterranean fever. Isr Med Assoc J. 2003;5(8):592-594.
48. Morell RJ, Kim HJ, Hood LJ, et al. Mutations in the connexin 26 gene (GJB2) among Ashkenazi Jews with nonsyndromic recessive deafness. N Engl J Med. 1998;339(21):1500-1505.
49. Lerer I, Sagi M, Malamud E, Levi H, Raas-Rothschild A, Abeliovich D. Contribution of connexin 26 mutations to nonsyndromic deafness in Ashkenazi patients and the variable phenotypic effect of the mutation 167delT. Am J Med Genet. 2000;95(1):53-56.
50. Gershoni-Baruch R, Rosenmann A, Droetto S, Holmes S, Tripathi RK, Spritz RA. Mutations of the tyrosinase gene in patients with oculocutaneous albinism from various ethnic groups in Israel. Am J Hum Genet. 1994;54(4):586-594.